Physicians should be aware of the increased risk of gallbladder or biliary disease associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), especially at the higher doses recommended for weight loss, according to an article published in JAMA Internal Medicine .

The systematic review and meta-analysis included 76 randomised clinical trials...